Cargando…

Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML

Chimeric antigen receptor T cells (CAR-T) targeting CD19 have achieved significant success in patients with B cell malignancies. To date, implementation of CAR-T in other indications remains challenging due to the lack of truly tumor-specific antigens as well as control of CAR-T activity in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meyer, Jan-Erik, Loff, Simon, Dietrich, Josephine, Spehr, Johannes, Jurado Jiménez, Gabriel, von Bonin, Malte, Ehninger, Gerhard, Cartellieri, Marc, Ehninger, Armin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274446/ https://www.ncbi.nlm.nih.gov/pubmed/34290907 http://dx.doi.org/10.1080/2162402X.2021.1945804

Ejemplares similares

Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells
por: Bachmann, Dominik, et al.
Publicado: (2017)

Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia
por: Loff, Simon, et al.
Publicado: (2020)

Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells
por: Mitwasi, Nicola, et al.
Publicado: (2017)

Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”
por: Feldmann, Anja, et al.
Publicado: (2017)

Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
por: Cartellieri, M, et al.
Publicado: (2016)

T cells engrafted with a UniCAR 28/z outperform UniCAR BB/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression
por: Kegler, Alexandra, et al.
Publicado: (2019)

Targeting CD10 on B-Cell Leukemia Using the Universal CAR T-Cell Platform (UniCAR)
por: Mitwasi, Nicola, et al.
Publicado: (2022)

A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR
por: Arndt, Claudia, et al.
Publicado: (2019)

UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells
por: Arndt, Claudia, et al.
Publicado: (2020)

Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells
por: Koristka, Stefanie, et al.
Publicado: (2019)

Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers
por: Loureiro, Liliana R., et al.
Publicado: (2020)

Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells
por: Loureiro, L. R., et al.
Publicado: (2018)

“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
por: Mitwasi, Nicola, et al.
Publicado: (2020)

An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells
por: Jureczek, Justyna, et al.
Publicado: (2019)

Highly Efficient Targeting of EGFR-Expressing Tumor Cells with UniCAR T Cells via Target Modules Based on Cetuximab(®)
por: Jureczek, Justyna, et al.
Publicado: (2020)

From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo
por: Albert, Susann, et al.
Publicado: (2018)

Chimeric antigen receptor T-cell therapy in acute myeloid leukemia
por: Koedam, Jan, et al.
Publicado: (2022)

CD81 costimulation skews CAR transduction toward naive T cells
por: Schultz, Liora M., et al.
Publicado: (2022)

Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape
por: Xie, Danni, et al.
Publicado: (2023)

Emerging CAR T Cell Strategies for the Treatment of AML
por: Vishwasrao, Paresh, et al.
Publicado: (2022)

The Black Hole: CAR T Cell Therapy in AML
por: Atilla, Erden, et al.
Publicado: (2023)

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
por: Ehninger, A, et al.
Publicado: (2014)

Characterization of a Novel Single-Chain Bispecific Antibody for Retargeting of T Cells to Tumor Cells via the TCR Co-Receptor CD8
por: Michalk, Irene, et al.
Publicado: (2014)

Biomarkers as targets for CAR-T/NK cell therapy in AML
por: Shao, Ruonan, et al.
Publicado: (2023)

CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells
por: Jin, Xin, et al.
Publicado: (2023)

Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy
por: Song, De-Gang, et al.
Publicado: (2012)

CD70 CAR T cells in AML: Form follows function
por: Mirazee, Justin, et al.
Publicado: (2022)

Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts
por: Aliperta, R, et al.
Publicado: (2015)

Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG+ AML
por: Yao, Sun, et al.
Publicado: (2019)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
por: Hofmann, Susanne, et al.
Publicado: (2019)

Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
por: Nixdorf, D., et al.
Publicado: (2023)

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells
por: Cai, Tianyu, et al.
Publicado: (2022)

Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells
por: Han, Yali, et al.
Publicado: (2018)

Conventional CARs versus modular CARs
por: Feldmann, Anja, et al.
Publicado: (2019)

A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy
por: Epperly, Rebecca, et al.
Publicado: (2020)

Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients
por: Marofi, Faroogh, et al.
Publicado: (2021)

Rapamycin Pretreatment Rescues the Bone Marrow AML Cell Elimination Capacity of CAR-T Cells
por: Nian, Zhigang, et al.
Publicado: (2021)

Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML
por: Pedersen, Maya Graham, et al.
Publicado: (2022)

BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity
por: Poussard, Margaux, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bcq7ruqkb0kktb53pisj4af6nf